Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769829 · ClinicalTrials.gov registry record
ImmuneSense™ IBD Study
A clinical trial, sponsored by Adaptive Biotechnologies.
- Terminated
- Registry status
- 484
- Enrollment target
NCT05769829 is a clinical trial that was terminated before completion, run by Adaptive Biotechnologies. The registered enrollment target is 484 participants.
The verdict
NCT05769829 was terminated before completion, sponsored by Adaptive Biotechnologies.
- TERMINATED
- Registry status
- 484 participants
- Enrollment target
Study Summary
This study will enroll adult and pediatric participants across 3 phases: Research phase, Clinical Validation (CV) and Analytical Validation (AV) phase. Sites selected to participate in the study will enroll participants in the either the Research phase or CV and AV phase. Research Phase will enroll participants in Cohort 1 Pre-diagnosis/+GI symptoms only. CV and AV phase will be open to enrollment in parallel. CV phase will enroll participants in Cohort 2 Diagnosed IBD, Pre-treatment, Cohort 3 Potential Cross-Reactive Diseases and Cohort 4 Healthy controls. AV phase will enroll participants in Cohort 2 Diagnosed IBD, Pre-treatment and Cohort 4 Healthy controls. Enrollment will be ongoing until sponsor notification for closure.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2023-08-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05769829
The ClinicalTrials.gov registry entry for NCT05769829 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptive Biotechnologies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05769829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05769829 about?
NCT05769829 is a clinical study titled "ImmuneSense™ IBD Study". This study will enroll adult and pediatric participants across 3 phases: Research phase, Clinical Validation (CV) and Analytical Validation (AV) phase. Sites selected to participate in the study will enroll participants in the either the Research phase or CV and AV phase. Research Phase will enroll...
What is the current status of trial NCT05769829?
This trial is currently terminated. The enrollment target is 484 participants. The study started on 2022-10-31. Estimated completion is 2023-08-14.
Who is sponsoring clinical trial NCT05769829?
This trial is sponsored by Adaptive Biotechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.